Researchers from the Centenary Institute and the University of Sydney have developed a modified version of the tuberculosis (TB) vaccine BCG that provided stronger and more sustained protection against TB. In preclinical tests in mice, the modified vaccine showed potential as a new approach to improving the effectiveness of TB vaccination.
Modified BCG Vaccine Enhances Protection Against Tuberculosis
Researchers from the Centenary Institute and the University of Sydney have developed a modified BCG vaccine that offers stronger and longer-lasting protection against tuberculosis (TB) in preclinical tests. This advancement could lead to improved TB vaccination strategies, which is significant for public health in Iran, where TB remains a concern.
👥 Key Players
📰 What Happened
Researchers have developed a modified version of the BCG vaccine that shows improved effectiveness against tuberculosis in preclinical tests. This advancement could lead to better vaccination strategies for TB.
- The modified BCG vaccine demonstrated stronger and longer-lasting protection against TB in mice.
- This research could pave the way for new vaccination approaches to combat tuberculosis.
💡 Why It Matters
📚 Background
Tuberculosis is a contagious bacterial infection that primarily affects the lungs and remains a significant public health challenge worldwide, including in Iran.
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%